Inhibition of amyloid β peptide / RAGE interaction at the blood-brain barrier

摘要

Small molecules are used to inhibit specific receptor-ligand interaction between Alzheimer's amyloid- peptide (A) and Receptor for Advanced Gly-cation Endproducts (RAGE). Objectives include treating Alzheimer's disease and other pathologies involving cerebral amyloid angiopathy; improving blood flow to or within the brain; decreasing the level of A in the brain; reducing neuropathology associated with Alzheimer's disease; reducing inflammation and/or oxidant stress in the brain; improving memory and/or learning; treating other conditions involving A/RAGE interaction at the blood-brain barrier, RAGE-mediated transport of A into the brain, or RAGE activation in brain vasculature and/or brain parenchyma (e.g., diabetic complications); or any combination thereof.